Regencell Bioscience
3 hedge funds and large institutions have $7.43K invested in Regencell Bioscience in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
4.28% less ownership
Funds ownership: 4.76% → 0.48% (-4.3%)
96% less capital invested
Capital invested by funds: $171K → $7.43K (-$164K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$96.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $6.3K | -$96.2K | -556,814 | -91% |
|
2
BlackRock
New York
| $1.07K | – | – | – |
|
3
Qube Research & Technologies (QRT)
London,
United Kingdom
| $64 | – | – | – |
|
RGC Hedge Fund Activity: Q1 2024 in Review
3 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q1 2024, worth a combined $7.43K — down 96% from $171K a quarter earlier.
Fund positioning in RGC was balanced in Q1 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $96.2K.
- 3 institutional investors held Regencell Bioscience (RGC) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $7.43K of Regencell Bioscience stock for Q1 2024, down 96% quarter-over-quarter.
- 0 funds opened new Regencell Bioscience positions in Q1 2024 and 0 closed out.
- The largest Regencell Bioscience seller in Q1 2024 was UBS Group, an estimated $96.2K sold.
Based on aggregated 13F filings for Q1 2024.